



(11) Publication number:

**0 318 281  
A3**

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: 88311118.9

(51) Int. Cl.<sup>5</sup>: A61K 31/70

(22) Date of filing: 24.11.88

(30) Priority: 25.11.87 US 125098  
09.09.88 US 242341(43) Date of publication of application:  
31.05.89 Bulletin 89/22(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE(88) Date of deferred publication of the search report:  
10.10.90 Bulletin 90/41(71) Applicant: HEM RESEARCH, INC.  
12280 Wilkins Avenue P.O. Box 2245  
Rockville, MD 20852(US)(72) Inventor: Carter, William A.  
1 Jaine Lane  
Birchrunville Pennsylvania 19421(US)(74) Representative: Hallybone, Huw George et al  
CARPMAELS AND RANSFORD 43  
Bloomsbury Square  
London WC1A 2RA(GB)

(54) Use of dsRNA in the prevention of viral escape.

(57) dsRNA reduces the phenomenon of viral escape and cellular damage attendant thereto. Viral escape is a process by which a virus or intracellular pathogen alters its host range or indirectly alters its susceptibility to antiviral or immunological therapies. Viruses do so by causing specific changes in their genomic/antigenic composition and/or by causing the elaboration of factors which enhance destructiveness of cells and their ability to multiply progeny virus. Animals susceptible to viral infections and pathology secondary to antigenic drift may have damage reduced by exposing them to dsRNA which prevents or substantially minimizes viral escape brought about through these mechanisms of molecular rearrangement and/or elaboration of factors which break down the natural host defenses.

EP 0 318 281 A3

# Best Available Copy



European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**  
which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

Application number

EP 88 31 1118

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
E	EP-A-0 300 680 (HEM RESEARCH INC.) * The whole document * --	1-9	A 61 K 31/70
E	EP-A-0 308 066 (HEM RESEARCH INC.) * The whole document * --	1-9	
D,P, X	EP-A-0 286 224(HEM RESEARCH INC.) * The whole document * --	1-9	
D,Y	EP-A-0 213 921 (HEM RESEARCH INC.) * The whole document * -- ./.	1-9	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K C 07 H
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 5-9 Claims searched incompletely: 1-4 Claims not searched: Reason for the limitation of the search:</p> <p>Claims 1-4: State biological mechanisms or rather modes of action but not specific therapeutical applications.</p>			
Place of search		Date of completion of the search	Examiner
The Hague		09-07-1990	FOERSTER
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application number

EP 88 31 3338 -2-

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	THE LANCET, no. 1/8545, June 6, 1987, pages 1286-1292; W.A. CARTER et al.: "Clinical, immunological, and virological effects of amplitgen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex"  * The whole article *  --	1-9	
D,P, A	THE LANCET, no. 1/8589, April 9, 1988, pages 790-794; W.E. ROBINSON Jr. et al.: "Antibody-dependent enhancement of human immunodeficiency virus type 1 infection"  * The whole article *	1-9	TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
A	PROC. NATL. ACAD. SCI. USA, vol. 83, September 1986, pages 7023-7027; W.G. ROBEY et al.: "Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody"  * The whole article *	1-9	
D,P, A	PROC. NATL. ACAD. SCI. USA, vol. 85, July 1988, pages 5200-5204; P.W. BERMAN et al.: "Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120"  * The whole article *	1-9	